Media Articles Related to Atenolol and Chlorthalidone (Atenolol / Chlorthalidone)
UF researchers use plants to study new ways of delivering drugs for pulmonary hypertension
Source: Endocrinology News From Medical News Today [2014.10.17]
UF researchers are using the leaves of plants to study new ways to deliver drugs that treat pulmonary hypertension, a disease with few treatment options, according to a study published online in...
Living closer to major roadways increases hypertension risk
Source: Hypertension News From Medical News Today [2014.10.03]
A new study in the Journal of the American Heart Association reports a significant association between living near a major roadway and the risk of high blood pressure.
Hypertension may be initiated by an autoimmune response
Source: Hypertension News From Medical News Today [2014.09.19]
High blood pressure is a major risk factor for heart attack, stroke, chronic heart failure, and kidney disease.
Dementia risk reduction through tobacco control and better prevention, detection and control of hypertension and diabetes
Source: Hypertension News From Medical News Today [2014.09.18]
The World Alzheimer Report 2014 'Dementia and Risk Reduction: An analysis of protective and modifiable factors', calls for dementia to be integrated into both global and national public health...
Men who improve their fitness levels can hold off development of hypertension
Source: Hypertension News From Medical News Today [2014.09.17]
A man's cardiorespiratory fitness can drastically delay the natural, age-associated increase of his blood pressure over his adult life span.
Published Studies Related to Atenolol and Chlorthalidone (Atenolol / Chlorthalidone)
Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. [2003.05]
BACKGROUND: There is evidence that diuretics and beta blockers impair glucose tolerance, whereas calcium channel blockers and angiotensin converting enzyme blockers lack this metabolic effect. We compared the effect of a combination therapy with a nondihydropyridine calcium channel blocker plus an angiotensin converting enzyme inhibitor and a beta blocker plus a diuretic on hemoglobin A(1c) (Hb A(1c)) in patients with type 2 diabetes and mild-to- moderate hypertension... CONCLUSIONS: HbA(1c) and other parameters of short- and long-term glycemic control were in a more favorable range after antihypertensive treatment with verapamil SR plus trandolapril as compared with atenolol plus chlorthalidone.
Effect of atenolol and reserpine on selected events in the systolic hypertension in the elderly program (SHEP). [1995.12]
The effect of atenolol and reserpine on incidence of strokes, coronary heart disease (CHD), cardiovascular disease (CVD), and mortality was assessed in 4736 persons aged 60 years and older with isolated systolic hypertension. Participants were randomized to either chlorthalidone (2371), with step-up to atenolol, or reserpine if needed, or placebo (2365)...
Randomised double-blind comparative study of efficacy and safety of hydroflumethiazide and reserpine and chlortalidone and atenolol in the treatment of mild to moderate hypertension in black patients. [1993.10]
This randomised, double-blind study compared the efficacy and safety of a fixed combination of hydroflumethiazide 50 mg and reserpine 0.125 mg (H-R) and chlortalidone 12.5 mg and atenolol 50 mg (C-A) in adult black patients with mild to moderate hypertension (a resting supine diastolic blood pressure (DBP) between 95 and 115 mmHg after a two week placebo washout period)...
Comparative effects of enalapril, atenolol and chlorthalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. 
Arterial hypertension and proteinuric nephropathy are common features in diabetic patients. In streptozotocin-diabetic rats, it has been possible to reduce the blood pressure and proteinuria by converting enzyme inhibitors, and so slowing the decline of kidney function... According to these results we can hypothesize that the inhibition of tissue angiotensin formation and its related change on the glomerular permeability, rather than renal and systemic hemodynamic features, seem to be the common mechanisms by which both enalapril as well as atenolol decrease the albuminuria in our patients.
[A comparative study of atenolol (Tenormin) and the combined preparation atenolol/chlorthalidone (Tenoretic Mite) in essential hypertension. A randomized double-blind study from general practice] [1990.04.09]
Two hundred and ninety-two hypertensive patients from general practice who had previously been treated with a diuretic with insufficient effect participated in a randomised trial for a period of three months. A total of 115 patients completed treatment with 50 mg atenolol (Tanormin) and 121 were treated with the combined preparation consisting of 50 mg atenolol and 12.5 mg chlothalidone (Tenoretic Mite) while 56 patients defected from the trial.
Clinical Trials Related to Atenolol and Chlorthalidone (Atenolol / Chlorthalidone)
Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome [Recruiting]
Marfan syndrome is an inherited connective tissue disorder with morbidity and mortality from
aortic dilation and dissection. The degree of aortic dilation and response to beta-blockade
(standard of care) vary in adults with Marfan syndrome. However, aortic stiffness is often
present, and can be a predictor of aortic dilation and cardiovascular complications. In
addition, adults with Marfan syndrome develop left ventricular diastolic dysfunction, which
can progress to heart failure. Aortic stiffness and diastolic dysfunction are important and
logical therapeutic targets in adults with Marfan syndrome.
TGF-beta mediates disease pathogenesis in Marfan syndrome and contributes to aortic
stiffness. The angiotensin receptor blocker, losartan, inhibits TGF-beta activity and
reverses aortic wall pathology in a Marfan mouse model. Losartan also decreases aortic
stiffness and improves diastolic function in hypertension, renal disease and hypertrophic
This trial is a randomized, double-blind trial of 50 adults with Marfan syndrome, treated
with 6 months of atenolol vs. losartan. Arterial tonometry for aortic stiffness and
echocardiography for diastolic function will be performed at the beginning and end of
treatment. A blood draw for serum markers of extracellular matrix turnover and inflammation
will also be performed at 0 and 6 months. We plan to determine whether losartan decreases
aortic stiffness and left ventricular diastolic dysfunction significantly more than
A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension [Recruiting]
This is a phase IV, prospective, multi-centric and randomized controlled study to compare
the effects of bisoprolol and atenolol on resting heart rate (RHR) and sympathetic nervous
system's (SNS) activity in subjects with essential hypertension. A total of 192 subjects are
planned to be enrolled in various centers in China.
Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina. [Recruiting]
Evaluation of The Effects of Nebivolol in Comparison to Atenolol on Wall Shear Stress and Rupture Prone Coronary Plaques [Recruiting]
Nebivolol is a novel blood pressure lowering drug with an additional effect on the inner
lining of blood vessels to release a compound called nitric oxide that can relax blood
vessels. Atenolol is a blood pressure reducing agent without the ability to release nitric
oxide and effect additional blood vessel relaxation.
The goal of this proposal is to compare Nebivolol and Atenolol with respect to the following
- Plaque within arteries supplying the heart in terms of its volume and composition as
assessed by ultrasound within these arteries.
- Ability of small arteries in the heart to open up and deliver an enhanced blood supply
in response to drug called Adenosine (routinely used in the cardiac catheterization
laboratory) as assessed by pressure and flow detecting catheters within these arteries.
- Ability of the inner lining of arteries that supply the heart to release a relaxing
compound called nitric oxide in response to injection of Acetylcholine (also used in
the cardiac catheterization laboratory) as assessed by squirting dye into these
- Local forces that affect blood flow in the arteries supplying the heart as assessed by
superimposing the above data into complex maps created offline at Georgia Institute of
It is likely that Nebivolol causes the plaque within arteries supplying the heart to change
from the 'vulnerable' type to the 'stable' type plaque. There are several features of
"vulnerable plaques" that can be detected in arteries of the heart using intravascular
ultrasound (a small ultrasound camera that goes in the arteries of the heart). The
investigators hypothesis is that Nebivolol will prove superior to Atenolol in reducing
'vulnerable plaques', improve blood flow within the small arteries and the health of inner
lining of these arteries at the 1 year time point. The investigators plan to enroll 20
patients into the study (26 patient including dropouts) who will be randomized in a 1: 1
manner to Nebivolol Vs Atenolol for 1 year and repeat evaluation at that time point.
Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol [Recruiting]
Marfan syndrome (MFS) is an inherited disorder of connective tissue with morbidity and
mortality from aortic dilatation and dissection. The current standard of care is
beta-blocker (BB) treatment and therapeutic target is heart rate. The degree of aortic
dilatation and response to BB vary in adults with MFS. However, aortic stiffness is often
present, and can be a predictor of aortic dilatation and cardiovascular complications.
Aortic stiffness is a logical therapeutic target in adults with MFS.
Transforming growth factor beta(TGF-beta) mediates disease pathogenesis in MFS and
contributes to aortic stiffness. Cross-talk between TGF-beta system and renin-angiotensin
system (RAS) has been demonstrated. The angiotensin receptor blocker (ARB), losartan,
inhibits TGF-beta activity and reverses aortic wall pathology in a Marfan mouse model. In a
small cohort study, the use of ARB therapy (losartan or irbesartan) significantly slowed the
rate of progressive aortic dilatation in patients with MFS, after BB therapy had failed to
prevent aortic root dilatation. In another study, angiotensin converting enzyme inhibitor,
perindopril, reduced both aortic stiffness and aortic root diameter in patients with MFS
taking standard BB therapy. Renin inhibitor, aliskiren, has not been studied to reduce
aortic stiffness and attenuate aortic dilatation in patients with MFS.
This trial is a randomized, open-label trial of 32 patients with Marfan syndrome, treated
with 6 months of aliskiren vs. negative controls in patients with MFS under atenolol
treatment. MRI for aortic pulsed wave velocity (PWV) and distensibility, measurements of
central BP (CBP) and augmentation index (AIx) will be performed at the beginning and end of
treatment. A blood drawn for serum markers of TGF-beta, extracellular matrix turnover and
inflammation will also be performed at 0 and 6 months. We plan to determine whether
aliskiren decreases aortic stiffness significantly more than negative controls in patients
with MFS under atenolol treatment.
Reports of Suspected Atenolol and Chlorthalidone (Atenolol / Chlorthalidone) Side Effects
Drug Ineffective (7),
Acute Myocardial Infarction (5),
Coronary Artery Disease (5),
Chest Pain (4),
Cough (4), more >>